

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Support, Training and Capacity Building for Infectious Disease Surveillance Networks in Affected Countries in Southeast Asia, Africa and Other Regions of the World**

**AGENCY:** Office of Public Health Emergency Preparedness, Office of the Secretary, HHS.

**ACTION:** Notice; Correction.

**SUMMARY:** The Office of Public Health Emergency Preparedness, HHS, published a notice in the **Federal Register** on Wednesday, March 8, 2006 announcing a forthcoming single source cooperative agreement award to the Pasteur Foundation, a not-for-profit affiliate of the Institut Pasteur to enhance the surveillance, epidemiological investigation and laboratory diagnostic capabilities in countries in S.E. Asia, Africa and other regions of the world. That notice contained an error by having omitted certain amounts of funding for enhancement of laboratory capacity at Institut Pasteur-Cambodia (IPC) in the second and third year of the project, for a virologist for IPC for three years, and for a senior project manager to coordinate the activities across the different countries that are involved in this project. This notice corrects the omission.

**FOR FURTHER INFORMATION CONTACT:** Lily O. Engstrom, 202-205-2882.

**Correction**

In the **Federal Register** of March 8, 2006, in FR Vol. 71, No. 45, on page 11665, correct the table to add the following omissions:

\$440,000 for enhancement of laboratory capacity at IPC for Year 2 and Year 3 (\$220,000 per year); \$210,000 for a virologist for IPC for three years (\$70,000 per year); and \$450,000 for a project manager for three years (\$150,000 per year).

The cooperative agreement resulting from this Funding Opportunity will be fully funded this fiscal year.

Dated: April 26, 2006.

**Stewart Simonson,**

*Assistant Secretary for Public Health Emergency Preparedness, Department of Health and Human Services.*

[FR Doc. E6-6595 Filed 5-1-06; 8:45 am]

**BILLING CODE 4150-37-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Disease Control and Prevention****Mine Safety and Health Research Advisory Committee: Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Mine Safety and Health Research Advisory Committee (MSHRAC).

*Times and Dates:* 9:00 a.m.–4:30 p.m., May 23, 2006. 8:30 a.m.–12:30 p.m., May 24, 2006.

*Place:* Four Points Hotel by Sheraton, 1201 K Street, NW., Washington, DC, 20005, telephone (202) 289-7600, fax (202) 289-3310.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people.

*Purpose:* This committee is charged with providing advice to the Secretary, Department of Health and Human Services, the Director, CDC, and the Director, National Institute for Occupational Safety and Health (NIOSH), on priorities in mine safety and health research, including grants and contracts for such research, 30 U.S.C. 812(b)(2), Section 102(b)(2).

*Matters to be Discussed:* The meeting will focus on NIOSH's current and planned research and prevention activities related to mine disaster prevention and response. The agenda will also include updates on partnership activities and reports from the Director and Associate Director.

Agenda items are subject to change as priorities dictate.

*For Further Information Contact:* Jeffery L. Kohler, Ph.D., Executive Secretary, MSHRAC, NIOSH, CDC, P.O. Box 18070, 626 Cochran Mill Road, Pittsburgh, Pennsylvania 15236, telephone (412) 386-5301, fax (412) 386-5300.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 24, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6-6649 Filed 5-1-06; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. 2006D-0169]

**Guidance for Industry: Guidance on the Labeling of Certain Uses of Lecithin Derived From Soy Under the Federal Food, Drug, and Cosmetic Act; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a guidance document entitled "Guidance on the Labeling of Certain Uses of Lecithin Derived From Soy Under the Federal Food, Drug, and Cosmetic Act" (the act). The guidance explains FDA's current thinking on the labeling of certain uses of lecithin derived from soy under the act. This guidance is part of FDA's implementation of the Food Allergen Labeling and Consumer Protection Act (FALCPA).

**DATES:** This guidance is final upon the date of publication. Submit written or electronic comments on the guidance document at any time.

**ADDRESSES:** Submit written requests for single copies of the guidance to the Office of Food Additive Safety (HFS-205), Center for Food Safety and Applied Nutrition, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1200, FAX: 301-436-2972. Send one self-addressed adhesive label to assist the office in processing your requests. Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>. To ensure a timelier processing of comments, FDA is no longer accepting comments submitted to the agency by e-mail. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance document.

**FOR FURTHER INFORMATION CONTACT:** Paul M. Kuznesof, Center for Food Safety and Applied Nutrition (HFS-205), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1289, or e-mail: [paul.kuznesof@fda.hhs.gov](mailto:paul.kuznesof@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:**

**I. Background**

FDA is announcing the availability of a guidance document entitled